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Background: Overactive bladder (OAB) involves a
complex set of symptoms with a lifetime prevalence of
any symptom in 30% of women and 20% of men.
Anticholinergic agents are associated with poor med-
ication persistence in OAB treatment.
Objective: This study evaluated the long-term
patterns of use and treatment failure in patients
prescribed anticholinergic agents for OAB.
Methods: This was a nonexperimental, retrospec-
tive cohort study. Medical, pharmacy, and eligibility
data from the IMS LifeLink Health Plans Claims
Database were used. Men and women aged Z18
years were eligible for inclusion with an International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation, diagnosis of OAB in any ﬁeld during the
patient study period from January 2005 to June 2010.
First documentation of a prescription ﬁlled between
July 2005 and June 2008 for an anticholinergic agent
was deﬁned as the index prescription. Other inclusion
criteria were: Z1 pharmacy claim for an anticholi-
nergic drug between July 2005 and June 2008;
continuous enrollment 6 months before the index
date, during which no anticholinergic drugs were
ﬁlled; and 24 months of follow-up from the index
prescription. Study outcomes were treatment failure,
discontinuation, switch, reinitiation, and adherence.
Treatment failure was deﬁned as having a treatment
discontinuation (ie, treatment gap of Z45 days) or
switching anticholinergic therapy.
Results: The analytic cohort comprised 103,250
patients with a mean age of 58.7 years. A majority
were female (73%) and privately insured (75%).
The vast majority of patients (91.7%) failed to
meet their treatment goals with their index anti-
cholinergic agent over the 24-month follow-up
period. Of these, 5.8% switched, 51.3% perm-
anently discontinued all anticholinergic agents,1744and 34.6% reinitiated treatment sometime after
45 days. The mean (SD) time to treatment failure
was 159 (216.0) days, with a mean of 1.3 (0.5)
unique anticholinergic agents per patient. Forty-
eight percent of patients demonstrated appropriate
adherence as determined by a medication posses-
sion ratio Z80%.
Conclusions: This study provides real-world data
on treatment patterns over 2 years in a large cohort of
patients diagnosed with OAB. Despite the potential
for better adherence with some anticholinergic agents,
these analyses suggest that such beneﬁts have not yet
been realized, and many patients end up without
effective pharmacotherapy. Thus, there is a need for
new therapies and strategies to increase persistence
and adherence to improve outcomes in OAB. (Clin
Ther. 2013;35:1744–1751)
& 2013 The Authors. Published by Elsevier, Inc.
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Overactive bladder (OAB) is a condition involving a
complex set of symptoms, including urinary incon-
tinence, urgency, and frequency. OAB often goes
undiagnosed and is associated with urinary tractVolume 35 Number 11
M.B. Chancellor et al.infections, skin infections, and skin irritations, as well
as a greater risk of falls.1 A recent, large-scale US
survey reported the lifetime prevalence for experienc-
ing any symptoms at 30% in women and 20% in
men. Moreover, 20% of women and almost 10% of
men reported suffering symptoms “often.”2
Anticholinergic agents are frequently associated
with poor rates of medication persistence when
used for the treatment of patients with OAB,3 and
it is common for persistence to markedly decrease
within the ﬁrst 6 months of initiating treatment.
Beyond 1 year of anticholinergic medication use,
patient persistence with treatment is reduced
further.4–8 In addition, increased adherence is the
strongest predictor of decreased health care costs in
the OAB population. A 10% increase in adherence
to anticholinergic medication has been associated
with a 5.6% reduction in total annual health care
costs.9
Although previous research has described the
course of treatment discontinuation and treatment
switching associated with the initial anticholinergic
prescribed, there is a paucity of research exploring
treatment patterns beyond use of the ﬁrst anticholi-
nergic. The objective of the present study was to
evaluate the dynamics of treatment failure in OAB
patients as related to their initial anticholinergic
therapy and after failure of that initial treatment.
METHODS
This was an observational study that used a nonex-
perimental, retrospective cohort design. The methods
were based on published articles with similar study
designs and widely accepted research practices.3,6,10
Patient records for this study were obtained from the
IMS LifeLink Health Plan Claims Database (IMS
Health, Danbury, Connecticut).
Data Source
The IMS LifeLink database contains information
on 468 million unique patients in total from 4102
health plans across the United States and represents
16 million lives annually. The vast majority of plans
included in the database are commercial (80%); a
small percentage are identiﬁed as Medicaid (3%) or
Medicare risk (1.7%) plans; and the remaining 15%
are categorized as “other.” For the present study, 3
component ﬁles encompassing medical, pharmacy,
and eligibility data were obtained for men and womenNovember 2013with a diagnosis of OAB between January 2005 and
June 2010.
The medical ﬁle contains data on diagnostic and
therapeutic services provided in both the inpatient
and outpatient settings and uses International Clas-
siﬁcation of Diseases, Ninth Revision, Clinical Mod-
iﬁcation (ICD-9-CM), codes (diagnosis codes),
Healthcare Common Procedure Coding System, and
Current Procedural Technology, 4th Edition, codes.
The pharmacy ﬁle contains data on prescription
drugs dispensed at both retail and mail-order phar-
macies, along with accompanying information re-
garding the characteristics of the drug dispensed,
including the National Drug Code, quantity dis-
pensed, and number of days supplied. Each claim
includes the date a prescription was ﬁlled, the
charged amount, and the amount paid. The eligibility
ﬁle contains demographic data and periods of eligi-
bility for each patient.
Inclusion Criteria
All men and women aged Z18 years were eligible
for inclusion in the analytic data set. OAB was
identiﬁed by a corresponding ICD-9-CM diagnosis
code during the study period. ICD-9-CM codes
identifying an OAB diagnosis included: 788.30,
788.31, 788.33–788.37, 788.39–788.43, 788.63,
596.51, 596.52, 596.55, and 596.59.
At least 1 pharmacy claim for an anticholinergic
drug indicated for OAB (Table I) between July 2005
and June 2008 was required for inclusion in the ﬁnal
analytic data set. The ﬁrst documentation of a
prescription ﬁlled between these dates was deﬁned
as the index prescription, and the date of the ﬁll was
deﬁned as the index date. In addition to a diag-
nosis of OAB and at least 1 prescription for an
anticholinergic medication, patients were required
to meet 3 other inclusion criteria: continuous en-
rollment for 6 months before the index date, a
minimum of 24 months of follow-up from the index
prescription date, and a “clean period” of 6 months
immediately preceding the index date during which
there was no documented prescription for an
anticholinergic drug.
Outcomes and Analyses
Study outcomes were considered over 24 months
after the index date. Those of interest included
treatment failure, consisting of discontinuations and1745
Table I. Anticholinergic drugs for the treatment
of overactive bladder.
Product Name Generic Name
Ditropan XLs* Oxybutynin chloride, oral
formulation
Detrol LAs† Tolterodine tartrate
Detrol †Tolterodine
Enablexs‡ Darifenacin
Gelniques§ Oxybutynin chloride, gel
formulation
Oxytrols§ Oxybutynin chloride, transdermal
formulation
Oxybutynin ER
Sancturas║ Trospium chloride
Sanctura XR™║ Trospium chloride ER
Toviaz™† Fesoterodine fumarate
VESIcares¶ Solifenacin succinate
ER ¼ extended release.
*Ditropan XL (Janssen Pharmaceuticals, Inc. Titusville,
New Jeresy).
†Detrol, Detrol LA and Toviaz (Pﬁzer Inc., New York,
New York).
‡Enablex (Novartis Pharma Stein AG, Stein, Switzerland).
§Gelnique and Oxytrol (Watson Pharma, Inc. Parsippany,
New Jersey).
║Sanctura and Sanctura XR (Allergan, Inc. Irvine,
California).
¶VESIcare (Astellas Pharma US, Inc. Northbrook,
Illinois).
Clinical Therapeuticsswitches; treatment reinitiation; time to treatment
failure; and medication adherence.
Treatment failure was deﬁned as the proportion of
patients who discontinued therapy or switched anti-
cholinergic medications. To be considered a discontin-
uation, patients were required to have a gap of at least
45 days in therapy based on ﬁll dates and days’
supply.3 Treatment switch was deﬁned as the ﬁrst
ﬁlled prescription for any anticholinergic medication
other than the previously prescribed medication
within 45 days of the last ﬁlled prescription. This
excluded any changes to a different dosage form
within the same drug class (eg, from oxybutynin
immediate release to oxybutynin extended release
[ER]). The corresponding time to treatment failure1746was estimated as the number of days between the
index date and the date of ﬁrst medication switch or
estimated discontinuation date.
Treatment reinitiation was deﬁned as documenta-
tion of a ﬁlled prescription for any anticholinergic
agent after a discontinuation period ofZ45 days. The
qualifying prescription could have been for the same
medication as previously prescribed or a new/different
anticholinergic medication.
Adherence to treatment was determined by using
the medication possession ratio (MPR), deﬁned as: (1)
the sum of the total number of days a medication was
supplied across anticholinergic claims except for the
last pharmacy claim divided by (2) the total number of
days from index to the ﬁll date of the last pharmacy
claim. The days’ supply of the last pharmacy claim was
excluded because it would artiﬁcially inﬂate compli-
ance because it would result in perfect compliance for
the last prescription. Thus, patients with only a single
prescription claim were excluded from the analysis.
Nonadherence was deﬁned as an MPR o80%.
Descriptive analyses were conducted on the full
cohort to characterize patients in terms of a range of
factors, including age, sex, geographic region, index
prescription year, index medication, plan type, med-
ical history, and comorbidities. Summary statistics of
the proportion of patients who failed, switched, and
reinitiated anticholinergic therapy over 3, 6, 12, 18,
and 24 months were estimated. The proportion of
patients who demonstrated good (Z80%) adherence
to medication was also estimated. Kaplan-Meier
methods were used to estimate time to treatment
failure over the 24-month period.RESULTS
Records of 103,250 patients with a diagnosis of OAB
met all inclusion criteria to form the study popula-
tion. Patients had a mean (SD) age of 58.7 (15.7)
years, and the majority of the study population was
female and privately insured. Of the study cohort,
39.6% were aged 18 to 54 years, 27.3% were aged
55 to 64 years, and 33.1% were aged Z65 years.
Men in this cohort were older than women (mean
age, 62.8 vs 57.2 years) (P o 0.0001). Most patients
initiated anticholinergic therapy in 2006 or 2007
(67%). One third of patients had a primary diagnosis
other than OAB at the index date. The most com-
monly prescribed medication was tolterodine ER,Volume 35 Number 11
Table II. Demographic characteristics and index
parameters.
Variable Value
Age, mean (SD), y 58.7 (15.7)
Female sex 74.9%
Plan type
Privately insured 75.2%
Medicaid 2.7%
Medicare 10.6%
Self-insured employer 10.9%
Unknown 0.6%
Region
East 21.4%
Midwest 34.9%
South 27.9%
West 15.7%
Charlson comorbidity index score,
mean (SD)
0.8 (1.3)*
Index year
2005 16.1%
2006 29.4%
2007 37.5%
2008 17.0%
Primary diagnosis (ICD-9-CM code)
Primary diagnosis not OAB-related 32.2%
Urinary frequency (788.41) 21.7%
Urinary incontinence, unspeciﬁed
(788.30)
12.5%
Urge incontinence (788.31) 8.6%
Hypertonicity of bladder (596.51) 6.9%
Mixed incontinence (788.33) 5.2%
Other† 12.9%
Index medication
Tolterodine ER 42.5%
Solifenacin 15.0%
Oxybutynin, oral 14.6%
Darifenacin 10.2%
Oxybutynin ER 10.0%
Tolterodine 2.5%
Trospium 2.4%
Oxybutynin TD 2.2%
Trospium ER 0.4%
OAB ¼ overactive bladder; ER ¼ extended release;
TD ¼ transdermal.
*Range of scoring from 0 to 40.
†International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation (ICD-9-CM), diagnoses accounting for o5%
of cohort each are: 596.59 (other functional disorder of
bladder), 788.43 (nocturia), and 788.63 (urgency of
urination); diagnoses representing o1% each of the
cohort are: 596.52 (low bladder compliance), 596.55
(detrusor sphincter dyssynergia), 788.34 (incontinence
without sensory awareness), 788.35 (post-void dribb-
ling), 788.36 (nocturnal enuresis), 788.37 (continuous
leakage), and 788.39 (other urinary incontinence).
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November 2013with almost one half (42%) of patients receiving this
as their index prescription (Table II).Treatment Failure
Almost all (92%) patients failed initial treatment with
their index prescription (Figure 1). Most treatment
failures were associated with treatment discontinuation
(86%) as opposed to a switch to another anticholinergic
therapy (5.8%). In addition, 33% of patients ﬁlled only 1
prescription, suggesting early failure (within the ﬁrst 30
days). The proportion of treatment failures was high
across all primary diagnoses, ranging from 89.0% to
96.5%, and across the anticholinergic therapies, with
90% failing to meet treatment goals with tolterodine ER
to 96% with oxybutynin transdermal (Table III). Given
this high rate of failure, outcomes were pooled across all
drugs to estimate the overall impact of anticholinergic
treatment for patients with OAB. The majority of
patients (71.0%) failed treatment within 6 months of
the index date, and the mean time to treatment failure
was 159 (216) days (Figure 2, Table IV). In an analysis
of treatment discontinuation only, 66.9% of the study
population had discontinued treatment at the end of 6
months, with this estimate increasing to 78.4% by the
end of year 1 and to 85.9% at the end of year 2. More
than one half (51.3%) had permanently discontinued
anticholinergic treatment by the end of 2 years, with
most discontinuations occurring in the ﬁrst 6 months.
Forty-eight percent of patients demonstrated appropriate
adherence as determined by an MPR Z80%.Switch Rate
Only 5.8% of the total cohort with a treatment
gap r45 days switched their index anticholinergic
over the 24-month period (Table IV). Most of the
switching occurred within the ﬁrst 3 months and
remained relatively stable over the follow-up period.
A large majority (81%) of patients who switched from
their index anticholinergic therapy experienced treat-
ment failure on a second-line anticholinergic therapy,
29% of whom tried a third agent and 71% who
permanently discontinued all anticholinergic use. In a
secondary analysis looking at any anticholinergic
switch regardless of treatment gap, 21% of patients
were found to have switched anticholinergic medica-
tion at least once during the study period. Patients
received a mean of 1.3 (0.5) unique anticholinergic
agents over the 24-month period.1747
8.3%
5.8%
51.3%
34.6%
91.7%
Continued index anticholinergic Treatment failure
Treatment switch Permanent discontinuation
Reinitiated treatment 
Figure 1. Overall treatment outcomes after initial choice of anticholinergic agent (N ¼ 103,250).
Clinical TherapeuticsTreatment Reinitiation
The percentage of patients who reinitiated anticho-
linergic treatment after a treatment gap of at least 45
days was 34.6%. Approximately one ﬁfth of patientsTable III. Association between treatment choice, compli
Drug or Drug
Category n
Adherence
Z80%
Over
(%
Tolterodine ER 43,902 51.1 90.
Solifenacin 15,533 49.4 90.
Oxybutynin oral 15,111 30.1 95.
Darifenacin 10,578 51.9 91.
Oxybutynin ER 10,350 51.8 90.
Tolterodine 2601 42.6 94.
Trospium 2510 42.4 95.
Oxybutynin TD 2246 43.4 96.
Trospium ER 419 54.3 93.
Overall 103,250 48.1* 91.
ER ¼ extended release; TD ¼ transdermal.
*Patients with only 1 prescription claim were excluded from
denominator of 60,506, of whom 29,096 had a medication p
1748(24.1%) restarted after 1 year, whereas 34.6% had
restarted by the end of the 2 years (Table III). Of those
who reinitiated anticholinergic therapy (n ¼ 35,723),
65.6% reinitiated with their index anticholinergicance, and failure outcomes.
Treatment Failure
all
)
Discontinuations
(%)
Switch
(%)
Reinitiation
(%)
4 84.7 5.7 34.1
4 85.2 5.2 35.6
8 91.1 4.7 33.4
7 85.7 6.0 33.9
6 84.0 6.7 34.2
7 85.1 9.7 36.3
0 88.1 6.9 41.5
3 88.8 7.5 39.5
6 87.1 6.4 36.3
7 85.9 5.8 34.6
the medication possession ratio analysis, resulting in a
ossession ratio Z80%.
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Figure 2. Treatment failure with anticholinergic
medication. Treatment failure was de-
fined as the proportion of patients
who discontinued therapy (ie, treat-
ment gap Z45 days) or who switched
anticholinergic medications. All pa-
tients were required to have a mini-
mum of 24 months’ continuous
eligibility from the index date.
M.B. Chancellor et al.agent whereas 34.4% reinitiated with a different
anticholinergic agent.
DISCUSSION
Current American Urological Association guidelines
for OAB recommend anticholinergic drugs as ﬁrst-line
pharmacologic treatments in persons who fail to
improve with behavioral therapies.11 This study
provides real-world data on patterns of anticholiner-
gic use over 2 years in a large cohort of patients
diagnosed with OAB. Over the course of 2 years,Table IV. Treatment failure over time. Unless otherwise
Patient No. 3 Months 6 Month
N in each period (divisor)* 103,250 103,250
Treatment failures 51,073 (49.5) 73,267 (71
Switched 3634 (3.5) 4241 (4.1
Discontinued 47,439 (45.9) 69,026 (66
Restarted 3814 (3.7) 12,817 (12
Discontinued permanently 43,625 (42.2) 56,209 (54
*By design, no patients were lost to follow-up.
November 2013almost all patients experienced at least 1 treatment
failure, and more than one half permanently discon-
tinued treatment. At least one half of these failures
and discontinuations occurred within the ﬁrst 6
months after treatment initiation. Treatment failure
was found to be high regardless of anticholinergic
therapy choice, and adherence was suboptimal.
Several studies have examined the rates of treat-
ment failure involving anticholinergic therapies over a
6- to 12-month period. Depending on the study
design, the rates of treatment failure range from
24.5% to 95%.3,6,7,10,12 Studies that estimated treat-
ment failure through patient surveys reported rela-
tively low treatment failure rates (24.5%–45.0%)13,14
compared with claims analyses that typically reported
12-month rates 480%.3,6,7,10,12 The low rates of
discontinuation reported in patient surveys are not
surprising because patients tend to overstate their
adherence to medication. In addition, although sur-
veys use patient self-report to analyze treatment fail-
ure for all anticholinergic agents, claims analyses have
focused on treatment failure pertaining only to the
ﬁrst anticholinergic. In the present study, we used
claims data to analyze treatment failure both for the
index anticholinergic and overall. During the 24-
month follow-up period, almost all patients failed to
improve with their index anticholinergic agent and
approximately one half (51.3%) permanently discon-
tinued all anticholinergic use.
One potential limitation of claims analyses of
anticholinergic use is that intermittent or “as-needed”
use is considered to be discontinued use of anticholi-
nergic therapy, likely overestimating the actual dis-
continuation rate. Although we deﬁned treatmentnoted, values are given as number (%).
s 12 Months 18 Months 24 Months
103,250 103,250 103,250
.0) 86,105 (83.4) 91,754 (88.9) 94,683 (91.7)
) 5128 (5.0) 5638 (5.5) 5979 (5.8)
.9) 80,977 (78.4) 86,116 (83.4) 88,704 (85.9)
.4) 24,834 (24.1) 31,407 (30.4) 35,723 (34.6)
.4) 56,143 (54.4) 54,709 (53.0) 52,981 (51.3)
1749
Clinical Therapeuticsdiscontinuation as a treatment gap of at least 45 days
between anticholinergic prescriptions, we analyzed the
proportion of anticholinergic users who had a docu-
mented prescription reﬁll occurring 445 days after
their last prescription ﬁll (ie, reinitiated use). Overall,
one third of patients reinitiated therapy during the
study period, with a majority reinitiating treatment
with their index anticholinergic.
Our ﬁndings are similar to those from an earlier
study by D’Souza et al3; however, rates of permanent
discontinuation are somewhat higher in our study at
12 months (54% vs 45%), and rates of medication
switches are almost one third the rate observed by
D’Souza et al (5.8% vs 13%). Such differences may be
explained by the deﬁnition of a treatment switch,
which included within-class drug formulation changes
in the study by D’Souza et al and the difference in
patient populations that were studied. In their study,
all patients prescribed tolterodine immediate release/
ER or oxybutynin immediate release/ER were eligible
for the study, yielding a population that included
54% with a diagnosis of OAB. In contrast, our
study required patients to have a diagnosis of OAB
and a prescription for an OAB medication to be
included. This ﬁnding suggests that anticholinergic
therapies are used broadly for indications other than
OAB. Nonetheless, a secondary analysis of any anti-
cholinergic switch, regardless of treatment gap, found
the switch rate to be much higher (21%).
Empirical studies of medication use have found
persistence to OAB medications to be very low across
medications that treat chronic conditions. A compa-
rative analysis by Yeaw et al10 assessed persistence
with 6 chronic therapies: oral antidiabetic agents,
angiotensin receptor blockers, statins, bispho-
sphonates, prostaglandins, and OAB medications.
Persistence with OAB medications was found to be
the lowest across the 6 drug classes. The 6-month
persistence rate for OAB medications was 32%
compared with 72% for oral antidiabetic agents.
Although there are differences in symptoms, adverse
events, and patient-reported outcomes across anticho-
linergic medications,15 failure and discontinuation
rates are very high, irrespective of the choice of
anticholinergic drug. Poor persistence with OAB
medications can have a negative impact on health-
related quality of life and increase the risk of medical
sequelae, such as urinary tract infections, falls, and
fractures. Benner et al13 reported that dissatisfaction1750with treatment outcomes was the most common reason
for anticholinergic discontinuation. A separate study
that examined treatment goals in anticholinergic users
found that less than one half of patients reportedly
achieved their goal of symptom relief after oxybutynin
therapy.16 In addition, achievement of treatment goals
was a strong predictor of treatment satisfaction. High
reported rates of treatment failure and patient
dissatisfaction with anticholinergic therapies reported
in the literature13,14 suggest that patients are experienc-
ing suboptimal therapy and symptom control. Effective
management of OAB must be a provider–patient
engagement that involves ongoing and open discussion
to understand and monitor the patient’s goals and
expectations of treatment. Treatment options provided
should be those that can help patients attain their goals.
Licensed OAB therapies such as botulinium toxin A,
sacral neuromodulation, and percutaneous tibial nerve
stimulation should be offered as alternatives to patients
who fail to meet their treatment goals with anticholi-
nergic medications. Because the present analysis was
based on claims data, clinical information such as
symptom severity was not available to permit capture
of this aspect, which may affect outcomes, including
adherence and discontinuation. In addition, the reasons
(eg, adverse events, limited efﬁcacy) for treatment
discontinuation, switching, and reinitiation of treat-
ment cannot be determined by using these administra-
tive data. This study nevertheless provides long-term
data to suggest that most patients do not experience the
intended beneﬁts of anticholinergic medications, even
when these agents are used as ﬁrst-line therapy.
CONCLUSIONS
This study provides real-world data on treatment
patterns over 2 years in a large cohort of patients
diagnosed with OAB. We found high rates of anti-
cholinergic treatment failure that started early in the
course of treatment and resulted in permanent dis-
continuation by 50% of anticholinergic users by the
end of 2 years. Despite the potential for better
adherence with some anticholinergic agents, our study
ﬁndings suggest that beneﬁts of anticholinergic use in
OAB are not being realized, and many patients end up
without further medication therapy.
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